1258833-77-0

Usage

Uses

Used in Pharmaceutical Industry:
6-bromo-8-fluoroisoquinoline is used as a pharmaceutical intermediate for the development of new drugs. Its unique structural features, including the presence of bromine and fluorine atoms, allow for the design of novel therapeutic agents with improved pharmacological properties.
Used in Agrochemical Industry:
In the agrochemical industry, 6-bromo-8-fluoroisoquinoline is utilized as a precursor for the synthesis of new pesticides. Its chemical properties can be harnessed to create innovative and effective pest control agents, contributing to sustainable agriculture practices.
Used in Organic Synthesis:
6-bromo-8-fluoroisoquinoline serves as a valuable precursor in organic synthesis for the production of other important compounds. Its unique structure and reactivity make it a versatile building block for the synthesis of various organic molecules with potential applications in different fields.
Understanding the properties and behavior of 6-bromo-8-fluoroisoquinoline is crucial for researchers and industries looking to leverage its potential utility in a wide range of applications, from drug development to agrochemical innovation and beyond.

Upstream product

• 112734-22-2 4-bromo-2-fluorobenzylamine 
• 1613147-80-0 N-(4-bromo-2-fluorobenzyl)-N-(2,2-dimethoxyethyl)benzenesulfonamide 
• 1183945-15-4 N-(4-bromo-2-fluorobenzyl)-2,2-dimethoxyethan-1-amine 
• 57848-46-1 4-bromo-2-fluorobenzaldehyde 

Downstream Products

• 1613147-83-3 (R)-5-(2-(tert-butoxycarbonyl)-8-fluoro-1,2,3,4-tetrahydroisoquinolin-6-yl)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)pyridin-2-amine 
• 1613147-79-7 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(8-fluoro-1,2,3,4-tetrahydroisoquinolin-6-yl)pyridin-2-amine 

Relevant academic research and scientific papers

WDR5 INHIBITORS AND MODULATORS

Isoquinolmone compounds and derivatives inhibit WDR5 and associated protein-protein interactions, and the compounds and their pharmaceutical compositions are useful for treating disorders and conditions in a subject, such as cancer cell proliferation.

TETRAHYDRO-BENZO[D]AZEPINE DERIVATIVES AS GPR120 MODULATORS

Novel tetrahydroisoquinoline and tetrahydrobenzazepine compounds of formula (I) capable of modulating the G-protein-coupled receptor GPR120, compositions comprising the compounds, and methods for their use for controlling insulin levelsin vivoand for the treatment of conditions such as of diabetes, inflammation, obesity and metabolic diseases. (I)

Structure–Activity Relationship Studies on (R)-PFI-2 Analogues as Inhibitors of Histone Lysine Methyltransferase SETD7

SETD7 is a histone H3K4 lysine methyltransferase involved in human gene regulation. Aberrant expression of SETD7 has been associated with various diseases, including cancer. Therefore, SETD7 is considered a good target for the development of new epigenetic drugs. To date, few selective small-molecule inhibitors have been reported that target SETD7, the most potent being (R)-PFI-2. Herein we report structure–activity relationship studies on (R)-PFI-2 and its analogues. A library of 29 structural analogues of (R)-PFI-2 was synthesized and evaluated for inhibition of recombinantly expressed human SETD7. The key interactions were found to be a salt bridge and a hydrogen bond formed between (R)-PFI-2′s NH2+ group and SETD7′s Asp256 and His252 residue, respectively.

CONDENSED RING DERIVATIVE, AND PREPARATION METHOD, INTERMEDIATE, PHARMACEUTICAL COMPOSITION AND USE THEREOF

Disclosed are a condensed ring derivative, and a preparation method, an intermediate, a pharmaceutical composition and a use thereof. The condensed ring derivative of the present invention has a significant inhibitive effect on URAT1, which can effectively alleviate or treat hyperuricemia and other related diseases.

Substituted ring compound and its method and use thereof

The invention provides a substituted cyclic compound as well as a use method and application thereof. The compound is a compound as shown in a formula (I) or stereoisomers, stereomers, tautomers, nitric oxides, solvates, metabolites and pharmaceutically acceptable salts or prodrugs of the compound as shown in the formula (I). The invention further provides a medicament composition containing the compound. The compound and the medicament composition are capable of regulating the activity of protein kinase in a biological sample body and are used for protecting, treating or relieving proliferative diseases of patients. The formula (I) is as shown in the specification.

SUBSTITUTED CYCLIC COMPOUNDS AND METHODS OF USE

The present invention provides novel substituted alkynyl compounds, pharmaceutical acceptable salts and formulations thereof useful in modulating the protein tyrosine kinase activity, and in modulating cellular activities such as proliferation, differentiation, apoptosis, migration and invasion. The invention also provides pharmaceutically acceptable compositions comprising such compounds and methods of using the compositions in the treatment of hyperproliferative disorders in mammals, especially humans.